It’s been a busy five months since cytokine therapy startup Mural Oncology landed its first big check after spinning out of Alkermes. Besides the usual new-business housekeeping, the company is in the ...

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune ...